Publication | Closed Access
CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice.
266
Citations
23
References
1998
Year
ImmunologyImmunodominanceAntigen ProcessingImmune SystemImmunotherapySynthetic ImmunologyIntranasal AdministrationViral HepatitisMucosal VaccinationAllergyAutoimmune DiseaseSubunit VaccinesAutoimmunityT Cell ImmunityMucosal ImmunityVaccinationCpg DnaHepatitisCpg OligodeoxynucleotidesVaccine DesignMedicineViral ImmunityMucosal Immune Responses
Mucosal immunity is difficult to induce with subunit vaccines unless such vaccines are administered with a mucosal adjuvant such as cholera toxin (CT); however, CT is toxic in humans. Synthetic oligodeoxynucleotides containing immunostimulatory CpG motifs (CpG) are potent adjuvants for the induction of Th1-like systemic immune responses against parenterally delivered proteins. Here, we show in mice that intranasal delivery of hepatitis B surface Ag, which alone has no effect, elicits good immune responses when given with CpG oligodeoxynucleotides and/or CT. Overall, CpG is superior to CT for the induction of humoral and cell-mediated systemic immunity as well as mucosal immune responses (IgA) at local (lung) and distant (feces) sites. Furthermore, CpG and CT act synergistically, giving stronger responses than those observed with 10 times more of either adjuvant alone. Ab isotypes were predominantly IgG1 (Th2-like) with CT, mixed IgG1/IgG2a (Th0) with CpG, and predominantly IgG2a (Th1-like) with CpG and CT together.
| Year | Citations | |
|---|---|---|
Page 1
Page 1